CCR5 and neoplasm: While pretreatment with CCR1 and CCR5 antagonists significantly reduced the T cell chemotaxes to the lungs, spleen, and tumor, we did not observe any difference on the biodistribution of CD11b+ myeloid cells (figure 2E).